Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson

Leukemia

Volumn 28, Issue 2, 2014, Pages 289-292

  Othus, M ^a   Kantarjian, H ^b   Petersdorf, S ^a   Ravandi, F ^b   Godwin, J ^c   Cortes, J ^b   Pierce, S ^a   Erba, H ^d   Faderl, S ^b   Appelbaum, F R ^a   Estey, E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

3+7; AML; high dose cytarabine; induction therapy; supportive care; treatment related mortality

Indexed keywords

CLOFARABINE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; SORAFENIB; TIPIFARNIB; TOPOTECAN; TROXACITABINE; VALSPODAR; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; HUMAN; INTENSIVE CARE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RELATED MORTALITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893788771     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.176     Document Type: Article

References (15)

1. Appelbaum F, Gundacker H, Head D, Slovak M, Willman C, Godwin J et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
2. Walter R, Othus M, Borthakur G, Ravandi F, Cortes J, Pierce S et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417-4423.
3. Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257-263.
4. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114-1124.
5. Fenaux P, Mufti G, Hellströ m-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
6. Platzbecker U, Germing U. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid Leukemia-a wise liaison?". Leukemia 2013, e-pub ahead of print 6 May 2013; doi:10.1038/leu.2013.140.
7. Pollyea D, Kohrt H, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2011; 26: 893-901.
8. Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
9. Quintas-Cardama A, Santos F, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2010; 25: 226-235.
10. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
11. Walter R, Othus M, Borthakur G, Ravandi F, Cortes J, Pierce S et al. Quantitative effect of age in predicting empirically-defined treatment-related mortality and resistance in newly diagnosed AML: case against age alone as primary determinant of treatment assignment. Blood 2010; 116: 2191, (ASH abstract # 2191).
12. Baden L. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia 2003; 17: 1038-1041.
13. Aperis G, Alivanis P. Posaconazole: a new antifungal weapon. Rev Recent Clin Trials 2011; 3: 204-219.
14. Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C et al. for the SEIFEM Group. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B Registry. Clin Infect Dis 2012; 55: 1515-1521.
15. Walsh T, Teppler H, Donowitz G, Maertens J, Baden L, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.